342 related articles for article (PubMed ID: 31877118)
1. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
[TBL] [Abstract][Full Text] [Related]
2. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
[TBL] [Abstract][Full Text] [Related]
3. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
4. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
Marston S; Copeland O; Gehmlich K; Schlossarek S; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):75-80. PubMed ID: 22057632
[TBL] [Abstract][Full Text] [Related]
5. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
6. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
[TBL] [Abstract][Full Text] [Related]
7. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
[TBL] [Abstract][Full Text] [Related]
8. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
9. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
10. Spatial and Functional Distribution of
Helms AS; Thompson AD; Glazier AA; Hafeez N; Kabani S; Rodriguez J; Yob JM; Woolcock H; Mazzarotto F; Lakdawala NK; Wittekind SG; Pereira AC; Jacoby DL; Colan SD; Ashley EA; Saberi S; Ware JS; Ingles J; Semsarian C; Michels M; Olivotto I; Ho CY; Day SM
Circ Genom Precis Med; 2020 Oct; 13(5):396-405. PubMed ID: 32841044
[TBL] [Abstract][Full Text] [Related]
11. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
12. Generation of bi-allelic MYBPC3 truncating mutant and isogenic control from an iPSC line of a patient with hypertrophic cardiomyopathy.
Warnecke N; Ulmer BM; Laufer SD; Shibamiya A; Krämer E; Neuber C; Hanke S; Behrens C; Loos M; Münch J; Kühnisch J; Klaassen S; Eschenhagen T; Patten-Hamel M; Carrier L; Mearini G
Stem Cell Res; 2021 Aug; 55():102489. PubMed ID: 34375846
[TBL] [Abstract][Full Text] [Related]
13. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy.
Carrier L; Bonne G; Bährend E; Yu B; Richard P; Niel F; Hainque B; Cruaud C; Gary F; Labeit S; Bouhour JB; Dubourg O; Desnos M; Hagège AA; Trent RJ; Komajda M; Fiszman M; Schwartz K
Circ Res; 1997 Mar; 80(3):427-34. PubMed ID: 9048664
[TBL] [Abstract][Full Text] [Related]
14. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.
Lekanne Deprez RH; Muurling-Vlietman JJ; Hruda J; Baars MJ; Wijnaendts LC; Stolte-Dijkstra I; Alders M; van Hagen JM
J Med Genet; 2006 Oct; 43(10):829-32. PubMed ID: 16679492
[TBL] [Abstract][Full Text] [Related]
15. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency.
Marston S; Copeland O; Jacques A; Livesey K; Tsang V; McKenna WJ; Jalilzadeh S; Carballo S; Redwood C; Watkins H
Circ Res; 2009 Jul; 105(3):219-22. PubMed ID: 19574547
[TBL] [Abstract][Full Text] [Related]
16. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations.
Pei J; Schuldt M; Nagyova E; Gu Z; El Bouhaddani S; Yiangou L; Jansen M; Calis JJA; Dorsch LM; Blok CS; van den Dungen NAM; Lansu N; Boukens BJ; Efimov IR; Michels M; Verhaar MC; de Weger R; Vink A; van Steenbeek FG; Baas AF; Davis RP; Uh HW; Kuster DWD; Cheng C; Mokry M; van der Velden J; Asselbergs FW; Harakalova M
Clin Epigenetics; 2021 Mar; 13(1):61. PubMed ID: 33757590
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
19. Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere.
Cheng Y; Wan X; McElfresh TA; Chen X; Gresham KS; Rosenbaum DS; Chandler MP; Stelzer JE
Am J Physiol Heart Circ Physiol; 2013 Jul; 305(1):H52-65. PubMed ID: 23666674
[TBL] [Abstract][Full Text] [Related]
20. Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.
Ribeiro M; Jager J; Furtado M; Carvalho T; Cabral JMS; Brito D; Carmo-Fonseca M; Martins S; da Rocha ST
Hum Cell; 2024 Jul; 37(4):1205-1214. PubMed ID: 38762696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
